Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Salvador Martín‐Algarra et al.|The Lancet|2012Cited by 3k
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Journal of Clinical Oncology|2013Cited by 112
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJean‐Jacques Grob, Axel Hauschild, Mayur M. Amonkar et al.|Annals of Oncology|2014Cited by 55
An Update on Overall Survival (Os) and Follow-On Therapies in Break-3, a Phase Iii, Randomized Trial: Dabrafenib (D) Vs. Dacarbazine (Dtic) in Patients (Pts) with Braf V600E Mutation-Positive Metastatic Melanoma (Mm)Axel Hauschild, Paul B. Chapman, J. Grobb et al.|Annals of Oncology|2014Cited by 37
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Unknown|2012Cited by 7